arrow
Y

Yueyin Pan

university of science and technology of china
H指数:45
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

BRD4 orchestrates the metabolic-epigenetic regulation of GM-CSF expression and secretion to drive PD-L1⁺ macrophage-mediated immune evasion in triple-negative breast cancer

BRD4调控GM-CSF表达和分泌的代谢-表观遗传学调节,以驱动三阴性乳腺癌中PD-L1⁺巨噬细胞介导的免疫逃逸。

2026-02-140
PRE
First-line serplulimab plus chemotherapy in extensive-stage small-cell lung cancer: Updated results and biomarker analysis from the ASTRUM-005 randomized clinical trial

一线serplulimab联合化疗治疗广泛期小细胞肺癌:ASTRUM-005随机临床试验的更新结果与生物标志物分析

2025-05-290
OAAI
A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer
2024-12-040
OAAI
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial

Fruquintinib联合紫杉醇与安慰剂联合紫杉醇治疗胃或胃食管交界处腺癌的比较: FRUTIGA随机3期试验

2024-06-011
PRE
Effects of sintilimab plus chemotherapy as fi rst-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 study
2024-06-012
OAAI
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial
2024-05-018
PRE
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm open-label, multicentre, phase 2 trial
2024-03-0119
PRE